International Cardiovascular Experts Present

Outcome-Optimizing Treatment Roadmaps for AF Patients with Renal, Bleeding, Cardiovascular, and Age-Related Vulnerabilities


Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

4.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in managing patients at risk for stroke in the setting of atrial fibrillation.

Release Date

October 3, 2016

Expiration Date

October 3, 2018

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period October 3, 2016 through October 3, 20168, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 18 segments totaling 4.0 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.


Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Commercial Support

Supported by an educational grant from Daiichi Sankyo, Boehringer Ingelheim, and the Pfizer-Bristo-Myers Squibb Cardiovascular Partnership.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. Complete Conference Management is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

Professor Samuel Z. Goldhaber, MD
Program Co-Chair

Section Head, Vascular Medicine
Director, Thrombosis Research Group
Cardiovascular Medicine
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA USA

Consultant: Boehringer Ingelheim, BMS, Daiichi, Janssen, Portola
Grant/Research Support: BMS, BTG, Daiichi, NHLBI, Thrombosis Research
Institute, BiO2 Medical

Professor Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Program Co-Chair

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Heart and Vascular Center
Professor of Medicine, Harvard Medical School
Boston, USA

Contracted Research: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Ischemix, Medtronic, Pfizer, Roche, Sanofi-aventis, The Medicines Company

Ingo Ahrens, MD
Head of Atherothrombosis, Inflammation, and Platelets
Associate Professor of Medicine, Interventional Cardiology
University of Freiburg
Freiburg, Germany

Nothing to disclose

Professor Felicita Andreotti, MD, PhD
Professor of Medicine
Catholic University in Rome
Roma, Italy

Consultant: Amgen, Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo

Carlos Aquiar, MD
New University of Lisbon
Department of Cardiology
Hospital de Santa Cruz
Carnaxide, Portugal

Speaker’s Bureau: BMS/Pfizer, Bayer
Advisory Board: BMS/Pfizer, Bayer, Daiichi Sankyo

Professor Harry R. Büller, MD, PhD
Department of Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands

Consultant: Daiichi Sankyo, Boehringer Ingelheim, Sanofi

Professor Christoph Bode, MD, PhD
Chair of Medicine
University of Freiburg
Freiburg, Germany

Honoraria: Boehringer Ingelheim, Daiichi Sankyo, Merck, Bayer

Professor Paolo Colonna, MD FESC
Department of Cardiology
Policlinico University of Bari
Bari, Italy

Advisory Board: Daiichi Sankyo, Boehringer Ingelheim, Bayer, Pfizer/BMS

Professor Raffaele De Caterina, MD, PhD
Chairman of Cardiology and Director
Postgraduate School of Cardiology
‘G d’Annunzio’ University in Chieti
Chiete, Italy

Honoraria and consulting: Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo

Robert P. Giugliano, MD, SM, FACC, FAHA
Senior Investigator with the TIMI Study Group
Harvard Medical School
Boston, MA, USA

Consultant: Amarin, American College of Cardiology, Amgen,
CVS Caremark, Daiichi-Sankyo, GlaxoSmithKline,
Lexicon, Merck, Portola, Pfizer, St Jude, Stealth Peptides
Grant/Research Support: Amgen, Merck
Honoraria for CME Lectures: Amgen, Daiichi-Sankyo, Merck

Professor Stefan Hohnloser, MD
Director, Department of Clinical Electrophysiology
J. W. Goethe University
Frankfurt, Germany

Consultant: Boehringer Ingelheim, BMS/Pfizer, Bayer, Daiichi Sankyo, Medtronic

Professor David Jimenez, MD, PhD
University of Alcalá de HenaresRamón y Cajal Hospital
Madrid, Spain

Nothing to disclose

Professor Marcel Levi, MD PhD
Professor of Medicine
University of Amsterdam
The Netherlands

Nothing to disclose

Professor Stavros Konstantinides, MD, PhD
Professor of Medicine
University Medical Center Mainz

Speaker: Bayer, Boehringer Ingelheim
Advisor: Bayer, Boehringer Ingelheim

Professor Jean Yves Le Heuzey, MD
Head of Arrhythmia Department
Georges Pompidou Européen Hospital
Paris, France

Nothing to disclose

Professor Leopoldo S. Piegas, MD, PhD
University of São Paulo School of Medicine
Livre-Docente FMUSP,HCor - Hospital do Coração
São Paulo, Brasil

Nothing to disclose

Irina Savelieva, MD
Division of Cardiac and Vascular Science
St George's Hospital
University of London
London, United Kingdom

Nothing to disclose

Professor Peter R. Sinnaeve, MD, PhD, FESC
Department of Cardiovascular Medicine
University Hospitals
Leuven, Belgium

Nothing to disclose

Professor Jan Steffel, MD, FESC, FHRS
Department of Cardiology
University Heart Center
Zurich, Switzerland

Consultant: Daiichi Sankyo, Bayer. BMS/Pfizer, Boehringer Ingelheim

Peter Verhamme, MD, PhD
University Hospital of Gasthuisberg
Leuven, Belgium

Consultant: Daiichi-Sankyo, Bayer, Boehringer Ingelheim
Speaker’s Bureau: Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Pfizer
Grant/Research Support: Bayer, Boehringer Ingelheim, Sanofi, LeoPharma

Professor Freek Verheugt, MD, PhD
Professor of Cardiology
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands

Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company
Speaker: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company

Professor Jeffrey I. Weitz, MD
McMaster University
Executive Director
Thrombosis & Atherosclerosis Research Institute
Hamilton, Ontario, Canada

Consultant: BMS/Pfizer. Boehringer Ingelheim, Bayer, Janssen, Maerck, Daiichio Sankyo
Advisory Bioards: BMS/Pfizer. Boehringer Ingelheim, Bayer, Janssen, Maerck, Daiichio Sankyo

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.
Program reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Explain the role of compliance and regimen adherence for treatment of VTE and for stroke prevention in AF; and the potential advantages of once-daily administration to improve long-term compliance;
    Appropriately risk-stratify patients with non-valvular AF, with a focus on the CHA2DS2-VASc and HAS-BLED risk scores that currently are recommended to guide anticoagulation management in AF;
    Apply factor Xa inhibition for stroke prevention in high risk patients with AF, including those with a previous TIA or stroke;
    Appreciate the under-recognition of the risk of stroke in patients with AF, and the failure to prophylax patients, even those meeting CHA2DS2-VASc criteria for anticoagulation; and, the need to introduce prophylaxis in many patients with a CHA2DS2-VASc score of 1 and virtually all patients with a score of 2 or greater;
    Outline the implications of the longitudinal Garfield Registry and its findings that under-treatment/under-anticoagulation of AF patients remains a serious public health issue.;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2016 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC



Key Program Topics Include:

ACC/AHA/ESC Guidelines

Atrial Fibrillation


Factor Xa Inhibitor
Intracerebral Hemorrhage
Myocardial infarction
Pulmonary embolism

RE-LY Trial
rhythm control
Valvular Atrial Fibrillation